Join us   Log in  

PHARMASPIRE - Volume 12, Issue 3, July-September, 2020

Pages: 104-107

Date of Publication: 10-Jun-2022

Print Article   Download XML  Download PDF

Efficacy of montelukast when added with inhaled corticosteroids on mild-to-moderate asthmatic patients

Author: Ravneet Kaur, Mandeep Kaur, Sourabh Kosey

Category: Pharmaceutics


Objective: Asthma is an inflammatory disease characterized by recurrent attacks of breathlessness and wheezing. Inhaled corticosteroids (ICS) play an important role in the management of asthma. Reduction of ICS dose with any other drug combination may therefore be of clinical significance. Methods: A total of 118 Patients with mild to moderate asthma were enrolled in this randomized controlled study from the pulmonology/ medicine unit in the tertiary care hospital. Results: Patients were randomized into two groups viz., control group(n=59) and the treatment group(n=59).Control group patients received budesonide 800 mg twice a day and the treatment patients received 400 mg budesonide twice a day along with Montelukast 10 mg. Pulmonary function test was assessed at the baseline and on follow up days. No significant difference was observed with respect to socioeconomic and educational status of patients between control and treatment groups. Improvement observed was more in control group value (43%) than in treatment group value (25%).Even though 12% FEV1 improvement were observed, the rate of improvement was not significant (p>0.5). There is no serious adverse drug reaction among the tested groups. Conclusion: The study concluded that addition of Montelukast 10 mg to the inhaled Budesonide is an effective and alternative treatment option to doubling the dose of inhaled Budesonide.

Keywords: Antileukotrienes, asthma, budesonide, FEV1 , inhaled corticosteroids, montelukast, spirometry


1. WHO. Chronic Respiratory Disease. Asthma. WHO; 2020. Available from:

2. Mehta AK, Sahrma RN. Asthma: Ayurvedic Cure, Herbal Remedies, Yoga and Meditation. Uttar Pradesh: B Jain Publishers; 2004. p. 38-9.

3. American Thoracic Society. What constitutes an adverse health effect of air pollution? Official statement of the American thoracic society. Am J Respir Crit Care Med 2000;161:665-73.

4. Dhamage SC, Perret JL, Custovic A. Epidemiology of asthma in children and adults. Front Pediatr 2019;7:246-61.

5. Nunes C, Pereira AM, Almeida MM. Asthma costs and social impacts. Asthma Res Pract 2017;3:2-11.

6. Antonicelli L, Bucca C, Neri M, De Benedetto F, Sabbatani P, Bonifazi F, et al. Asthma severity and medical resource utilisation. Eur Respir J 2004;23:723-9.

7. British thoracic society guidelines for the management of asthma: A summary. BMJ 2000;306:776-82.

8. Carl JC, Myers TR, Kirchner HL, Kercsmar CM. Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. J Pediatr 2003;143:731-6.

9. Chinn S, Burney P, Jarvis D, Luczynska C. Variation in bronchial responsiveness in the European community respiratory health survey (ECRHS). Eur Respir J 1997;10:2495-501.

10. Cohn L, Elias JA, Chupp GL. Asthma: Mechanisms of disease persistence and progression. Annu Rev Immunol 2004;22:789-815.

11. Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of longacting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev 2010;5:650-7.

12. Federico MJ, Covar RA, Brown EE, Leung DY, Spahn JD. Racial differences in T-lymphocyte response to glucocorticoids. Chest 2005;127:571-8.

13. Gabhainn SN, Godeau E, Roberts C, Smith R, Currie D, Picket W, et al. Inequalities in Young People’s Health: HBSC International Report from the 2005/2006 Survey. Geneva, Switzerland: World Health Organization; 2008.

14. Johansson SA, Dahl R. A double-blind dose response study of budesonide by inhalation in the patients with bronchial asthma. Allergy 1998;43:173-8.